Pricing Log in Create free account

Adaptimmune Therapeutics PLC (ADAPY) vs Akari Therapeutics PLC (AKTX)

Adaptimmune Therapeutics PLC and Akari Therapeutics PLC are both Biotechnology companies. Adaptimmune Therapeutics PLC and Akari Therapeutics PLC are of similar size ($14.6M and $13.6M). Akari Therapeutics PLC has the higher net margin (0.00% vs −262.5%) and the lower return on invested capital (−167.9% vs 0.00%). Across the 13 metrics below, Akari Therapeutics PLC leads on 7 and Adaptimmune Therapeutics PLC on 6.

Valuation

Metric ADAPY AKTX Biotechnology median
P/E n/m n/m 10.60
P/S 0.08 n/m 9.40
P/B n/m 0.77 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 0.08 n/m 9.02
Earnings yield (3,250.00%) (316.53%) (32.88%)
Free cash flow yield (3,648.13%) (75.80%) (23.13%)

Profitability

Metric ADAPY AKTX Biotechnology median
Gross margin 94.81% 0.00% 68.51%
Operating margin (427.75%) 0.00% 0.00%
Net margin (262.46%) 0.00% 0.00%
Free cash flow margin (294.49%) 0.00% 0.00%
Return on equity (1,349.52%) (140.09%) (51.96%)
Return on assets 0.00% (69.16%) (46.06%)
Return on invested capital 0.00% (167.93%) 0.00%

Growth

Metric ADAPY AKTX Biotechnology median
Revenue growth (TTM) (53.99%) — 6.76%
EPS growth (last fiscal year) 142.86% 68.99% 29.88%
Revenue growth, 5-year CAGR 8.40% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ADAPY AKTX Biotechnology median
Debt to equity (0.36) 0.04 0.00
Current ratio 1.52 0.60 4.97
Net debt to EBITDA 0.47 0.27 1.01

Dividend

Metric ADAPY AKTX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ADAPY AKTX Biotechnology median
Market cap 14.55m 13.56m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack